This new CPB states that denosumab (Prolia) is considered medically necessary when criteria are met for the treatment of post-menopausal women with osteoporosis who are at high risk for fractures, for bone metastases from breast cancer or multiple myeloma, and for prevention of osteoporosis in persons receiving aromatase inhibitors.